Indegene Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Efficient capital deployment (ROCE 18.8%)
- Attractively valued vs sector (P/E 33.1x vs industry 50.2x)
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Dividend - Rs 2.25 Per Share
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 2 Per Share
Annual General Meeting
Latest News
All newsIndegene wins Frost & Sullivan AI leadership award
*Indegene wins Frost & Sullivan AI leadership award*. The company received the 2026 Global Enabling Technology Leadership Recognition for its **AI-powered pharma commercialization** solutions. The award highlights Indegene's innovation in digital health tech, though no financial impact was disclosed. 📊 *STOCKS:* $INDEGENE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Awards
Indegene announces Digital Summit 2026 in Philadelphia
*Indegene announces Digital Summit 2026 in Philadelphia*. The event is scheduled for October 06, 2026, at the National Constitution Center. It aims to showcase advancements in digital health solutions and stakeholder engagement. While positive for brand visibility, no financial impact is indicated. 📊 *STOCKS:* $INDEGENE | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #Event
Indegene hosts analyst and investor meet.
*Indegene hosts analyst and investor meet.* The company shared updates during a recent investor interaction. No major financial announcements or strategic shifts were disclosed. Event scheduled per routine corporate communication. 📊 *STOCKS:* $INDIGEN | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #AnalystMeet
Indegene hosts analyst and investor meet.
*Indegene hosts analyst and investor meet.* The company provided updates during its recent investor interaction. No major financial announcements or guidance revisions were disclosed. The session focused on business operations and market positioning. 📊 *STOCKS:* $IDEGENE | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #AnalystMeet
Indegene hosts analyst and investor meet
*Indegene hosts analyst and investor meet* to discuss business updates and strategy. The company shared recordings of the session for investor access. No new financial data or guidance was disclosed. This event is informational in nature with no immediate market-moving triggers. 📊 *STOCKS:* $IDEGENE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnalystMeet
Indegene to host analyst and investor meet
*Indegene to host analyst and investor meet.* The company has announced a schedule for its upcoming analyst and institutional investor call. Details on business performance and strategy may be discussed. No major financial announcements or operational updates were disclosed. 📊 *STOCKS:* INDEGENE | 🏢 *SECTOR:* Corporate | #LOWIMPACT #InvestorMeet
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.0K Cr 6.5% | ₹942 Cr 17.2% | ₹804 Cr 5.7% | ₹761 Cr 0.7% | ₹756 Cr 5.0% | ₹720 Cr 4.8% | ₹687 Cr 1.6% | ₹676 Cr |
| Op. Profit | ₹164 Cr 2.5% | ₹160 Cr 13.5% | ₹141 Cr 9.0% | ₹155 Cr 4.7% | ₹148 Cr 12.1% | ₹132 Cr 4.8% | ₹126 Cr 2.3% | ₹129 Cr |
| OPM | 16.0% 5.9% | 17.0% 0.0% | 17.0% 15.0% | 20.0% 0.0% | 20.0% 11.1% | 18.0% 0.0% | 18.0% 5.3% | 19.0% |
| Net Profit | ₹80 Cr 22.3% | ₹103 Cr 1.0% | ₹102 Cr 12.1% | ₹116 Cr 1.7% | ₹118 Cr 7.3% | ₹110 Cr 19.6% | ₹92 Cr 4.5% | ₹88 Cr |
| EPS (₹) | 3.31 22.7% | 4.28 0.7% | 4.25 12.4% | 4.85 1.0% | 4.9 7.0% | 4.58 19.6% | 3.83 4.4% | 3.67 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.5K Cr 23.6% | ₹2.8K Cr 9.6% | ₹2.6K Cr 12.3% | ₹2.3K Cr 38.5% | ₹1.7K Cr 72.4% | ₹966 Cr 50.2% | ₹643 Cr 16.3% | ₹553 Cr |
| Expenses | ₹2.9K Cr 26.2% | ₹2.3K Cr 10.0% | ₹2.1K Cr 9.1% | ₹1.9K Cr 38.6% | ₹1.4K Cr 87.2% | ₹736 Cr 47.5% | ₹499 Cr 2.3% | ₹511 Cr |
| Op. Profit | ₹619 Cr 13.0% | ₹548 Cr 8.5% | ₹505 Cr 27.5% | ₹396 Cr 38.0% | ₹287 Cr 24.8% | ₹230 Cr 59.7% | ₹144 Cr 242.9% | ₹42 Cr |
| OPM | 18.0% 5.3% | 19.0% 5.0% | 20.0% 17.6% | 17.0% 0.0% | 17.0% 29.2% | 24.0% 9.1% | 22.0% 175.0% | 8.0% |
| Other Income | ₹52 Cr 44.7% | ₹94 Cr 19.0% | ₹79 Cr 36.2% | ₹58 Cr 376.2% | ₹-21 Cr 600.0% | ₹-3 Cr 97.1% | ₹-102 Cr 1557.1% | ₹7 Cr |
| Interest | ₹19 Cr 13.6% | ₹22 Cr 55.1% | ₹49 Cr 58.1% | ₹31 Cr 416.7% | ₹6 Cr 14.3% | ₹7 Cr 22.2% | ₹9 Cr 50.0% | ₹6 Cr |
| Depreciation | ₹126 Cr 57.5% | ₹80 Cr 5.3% | ₹76 Cr 26.7% | ₹60 Cr 81.8% | ₹33 Cr 26.9% | ₹26 Cr 36.8% | ₹19 Cr 11.8% | ₹17 Cr |
| PBT | ₹525 Cr 2.6% | ₹539 Cr 17.4% | ₹459 Cr 26.4% | ₹363 Cr 60.6% | ₹226 Cr 15.9% | ₹195 Cr 1292.9% | ₹14 Cr 46.2% | ₹26 Cr |
| Tax % | 24.0% 4.0% | 25.0% 7.4% | 27.0% 0.0% | 27.0% 3.6% | 28.0% 21.7% | 23.0% 88.0% | 191.0% 324.4% | 45.0% |
| Net Profit | ₹401 Cr 1.5% | ₹407 Cr 20.8% | ₹337 Cr 26.7% | ₹266 Cr 63.2% | ₹163 Cr 9.4% | ₹149 Cr 1341.7% | ₹-12 Cr 185.7% | ₹14 Cr |
| EPS (₹) | 16.65 1.8% | 16.95 12.0% | 15.14 26.3% | 11.99 61.2% | 7.44 1.5% | 7.55 2459.4% | -0.32 145.1% | 0.71 |
| Div Payout | 13.0% 8.3% | 12.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||
| Equity Capital | ₹48 Cr 0.0% | ₹48 Cr 9.1% | ₹44 Cr 0.0% | ₹44 Cr 12471.4% | ₹0.35 Cr 12.9% | ₹0.31 Cr 0.0% | ₹0.31 Cr 0.0% | ₹0.31 Cr |
| Reserves | ₹3.1K Cr 20.4% | ₹2.6K Cr 85.4% | ₹1.4K Cr 35.8% | ₹1.0K Cr 33.5% | ₹764 Cr 135.8% | ₹324 Cr 408.6% | ₹-105 Cr 243.8% | ₹73 Cr |
| Borrowings | ₹144 Cr 41.2% | ₹102 Cr 79.2% | ₹490 Cr 2.4% | ₹502 Cr 660.6% | ₹66 Cr 29.4% | ₹51 Cr 89.4% | ₹483 Cr 228.6% | ₹147 Cr |
| Other Liabilities | ₹1.3K Cr 119.5% | ₹609 Cr 2.9% | ₹627 Cr 1.7% | ₹638 Cr 21.8% | ₹524 Cr 138.2% | ₹220 Cr 0.9% | ₹222 Cr 105.6% | ₹108 Cr |
| Total Liabilities | ₹4.6K Cr 38.9% | ₹3.3K Cr 30.6% | ₹2.5K Cr 15.5% | ₹2.2K Cr 62.9% | ₹1.4K Cr 127.0% | ₹596 Cr 0.7% | ₹600 Cr 82.4% | ₹329 Cr |
Assets | ||||||||
| Fixed Assets | ₹1.8K Cr 167.3% | ₹678 Cr 5.0% | ₹646 Cr 2.7% | ₹664 Cr 381.2% | ₹138 Cr 60.5% | ₹86 Cr 27.7% | ₹119 Cr 14.4% | ₹104 Cr |
| CWIP | ₹12 Cr 200.0% | ₹4 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹1.1K Cr 14.7% | ₹1.3K Cr 62.1% | ₹796 Cr 29.6% | ₹614 Cr 411.7% | ₹120 Cr | ₹0 Cr 100.0% | ₹13 Cr | ₹0 Cr |
| Other Assets | ₹1.7K Cr 25.2% | ₹1.4K Cr 22.8% | ₹1.1K Cr 19.1% | ₹926 Cr 15.5% | ₹1.1K Cr 114.9% | ₹510 Cr 9.0% | ₹468 Cr 108.0% | ₹225 Cr |
| Total Assets | ₹4.6K Cr 38.9% | ₹3.3K Cr 30.6% | ₹2.5K Cr 15.5% | ₹2.2K Cr 62.9% | ₹1.4K Cr 127.0% | ₹596 Cr 0.7% | ₹600 Cr 82.4% | ₹329 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹651 Cr 47.3% | ₹442 Cr 13.0% | ₹508 Cr 290.8% | ₹130 Cr 56.2% | ₹297 Cr 72.7% | ₹172 Cr 681.8% | ₹22 Cr 66.2% | ₹65 Cr |
| Investing CF | ₹-508 Cr 25.0% | ₹-677 Cr 107.7% | ₹-326 Cr 63.6% | ₹-896 Cr 467.1% | ₹-158 Cr 95.1% | ₹-81 Cr 406.3% | ₹-16 Cr 11.1% | ₹-18 Cr |
| Financing CF | ₹-83 Cr 128.8% | ₹288 Cr 536.4% | ₹-66 Cr 119.8% | ₹333 Cr 42.9% | ₹233 Cr 276.5% | ₹-132 Cr 197.1% | ₹136 Cr 747.6% | ₹-21 Cr |
| Net Cash Flow | ₹60 Cr 15.4% | ₹52 Cr 54.8% | ₹115 Cr 126.6% | ₹-433 Cr 216.1% | ₹373 Cr 1032.5% | ₹-40 Cr 128.0% | ₹143 Cr 472.0% | ₹25 Cr |
| Free Cash Flow | ₹606 Cr 47.1% | ₹412 Cr 17.1% | ₹497 Cr 347.7% | ₹111 Cr 59.2% | ₹272 Cr 80.1% | ₹151 Cr 843.8% | ₹16 Cr 66.7% | ₹48 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102d 5.2% | 97d 6.6% | 91d 10.8% | 102d 5.2% | 97d 10.2% | 108d 15.0% | 127d 111.7% | 60d |
| Inventory Days | — | — | — | — | — | — | — | — |
| Days Payable | — | — | — | — | — | — | — | — |
| Cash Conv. Cycle | 102d 5.2% | 97d 6.6% | 91d 10.8% | 102d 5.2% | 97d 10.2% | 108d 15.0% | 127d 111.7% | 60d |
| Working Capital Days | 5d 87.2% | 39d 44.4% | 27d 34.1% | 41d 272.7% | 11d 75.6% | 45d 1000.0% | -5d 28.6% | -7d |
| ROCE | 19.0% 24.0% | 25.0% 13.8% | 29.0% 12.1% | 33.0% 28.3% | 46.0% 16.4% | 55.0% 48.6% | 37.0% | — |
Source: Screener.in · Lower days = better efficiency
About Indegene Limited
Incorporated in 1998, Indegene Ltd provides solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and health care organizations[1]
HealthcareHealthcare Services